Eaddy Michael T, Druss Benjamin G, Sarnes Matthew W, Regan Timothy S, Frankum Laura E
Applied Health Outcomes, 3488 East Lake Rd., Suite 201, Palm Harbor, FL 34685, USA.
J Manag Care Pharm. 2005 Mar;11(2):145-50. doi: 10.18553/jmcp.2005.11.2.145.
Administrative claims data analysis performed in the early 1990s found lower total medical costs for patients with depression who remained on antidepressant therapy with selective serotonin reuptake inhibitors (SSRIs) for at least 90 days compared with patients who discontinued therapy prior to 60 days. Over the past decade, many changes in the health care system have occurred that might impact the reproducibility of these findings. The purpose of this study was to investigate the association between SSRI utilization patterns and the use of health care services in the managed care environment.
A large managed care claims database was used to identify patients receiving 2 or more SSRI prescriptions between June 2001 and December 2002. In order to ensure that patients were newly started on SSRI therapy, patients were required to have 6 months of enrollment data prior to their index date, without evidence of antidepressant therapy. Continuous enrollment for 12 months following their index prescription was also required. Patients with schizophrenia, bipolar disorder, or who received antipsychotic medications were excluded from this analysis. Patients were placed into 1 of 5 mutually exclusive antidepressant utilization cohorts: (1) <90 days, (2) e 90 days, (3) titration, (4) partial compliance, and (5) therapy change. Total medical costs, with and without pharmacy costs, were then compared between antidepressant utilization cohorts for 12 months of claims data.
There were 65,753 patients included in the study. Medical charges without pharmacy charges were lowest in the e 90-day cohort ($5,143) compared with the partial compliance ($5,909, P<0.05), <90-day ($6,289, P<0.001), titration ($6,375, P<0.001), and therapy change ($7,858, P<0.001) cohorts. Differences in total medical charges without pharmacy charges were primarily influenced by inpatient charges. The addition of pharmacy charges, including the charges for antidepressants, resulted in total medical charges that were not statistically different for the e 90-day cohort compared with the <90-day cohort, $7,454 and $7,829, respectively, P=0.606.
Medical charges without pharmacy charges were lower for patients remaining on antidepressant drug therapy for at least 90 continuous days compared with patients who used antidepressants for less than 90 continuous days, but total health care charges, including pharmacy charges, were not different between the 2 groups.
20世纪90年代初进行的行政索赔数据分析发现,与在60天前停药的抑郁症患者相比,持续使用选择性5-羟色胺再摄取抑制剂(SSRI)进行抗抑郁治疗至少90天的患者的总医疗费用更低。在过去十年中,医疗保健系统发生了许多变化,这可能会影响这些研究结果的可重复性。本研究的目的是调查在管理式医疗环境中SSRI使用模式与医疗服务使用之间的关联。
使用一个大型管理式医疗索赔数据库来识别在2001年6月至2002年12月期间接受2种或更多SSRI处方的患者。为确保患者是新开始接受SSRI治疗,要求患者在其索引日期前有6个月的参保数据,且无抗抑郁治疗证据。还要求在其索引处方后连续参保12个月。患有精神分裂症、双相情感障碍或接受抗精神病药物治疗的患者被排除在本分析之外。患者被分为5个相互排斥的抗抑郁药使用队列之一:(1)<90天,(2)≥90天,(3)滴定,(4)部分依从,和(5)治疗改变。然后比较抗抑郁药使用队列之间12个月索赔数据的总医疗费用(包括和不包括药房费用)。
该研究纳入了65753名患者。不包括药房费用的医疗费用在≥90天队列中最低(5143美元),与部分依从队列(5909美元,P<0.05)、<90天队列(6289美元,P<0.001)、滴定队列(6375美元,P<0.001)和治疗改变队列(7858美元,P<0.001)相比。不包括药房费用的总医疗费用差异主要受住院费用影响。加上药房费用,包括抗抑郁药费用,≥90天队列的总医疗费用与<90天队列相比无统计学差异,分别为7454美元和7829美元,P=0.606。
与连续使用抗抑郁药物少于90天的患者相比,连续使用抗抑郁药物治疗至少90天的患者不包括药房费用的医疗费用较低,但两组的总医疗费用(包括药房费用)无差异。